Alabama's Only Proton Therapy Center Treats First Patient with Varian ProBeam

PALO ALTO, Calif., March 17, 2020 -- (Healthcare Sales &Marketing Network) -- Varian (NYSE: VAR) announced today, Proton International at UAB has now treated its first cancer patient with the Varian ProBeam® Compact proton therapy system. The center,... Devices, Oncology Varian Medical Systems, ProBeam, proton therapy, radiotherapy
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news

Related Links:

Discussion: Incorporation of PBT into our existing cancer center allowed for multidisciplinary oncologic treatment of a diverse population of patients. Insurance coverage for PBT presents as a significant hurdle and improvements are needed to provide more timely access to necessary oncologic care.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Whole-pelvis pencil beam scanning (PBS) proton therapy is utilized in both the intact and post-operative settings in patients with prostate cancer. As whole pelvis prostate radiotherapy has traditionally been delivered with standard photon beams, limited evidence and technical descriptions have been reported regarding the use of proton therapy. Here we present two robust three-field treatment planning approaches utilized to maximize target coverage in the presence of anatomic and delivery uncertainties.
Source: Medical Dosimetry - Category: Radiology Authors: Source Type: research
To investigate the role of intensity-modulated proton therapy (IMPT) compared to volumetric modulated arc therapy (VMAT), realised with RapidArc and RapidPlan methods (RA_RP) for neoadjuvant radiotherapy in lo...
Source: Radiation Oncology - Category: Cancer & Oncology Authors: Tags: Research Source Type: research
The use of a specific treatment technique in radiation therapy is mainly motivated by the achievable dose conformity to the target and the overall integral dose. Proton therapy offers a highly conformal and comprehensive treatment option with a lower integral dose (reduced low-dose bath) to organs at risk (OARs). Consequently, given the proximity of cardiopulmonary structures, proton therapy has been discussed as a treatment alternative for breast cancer patients [1 –3]. Treatment planning studies, comparing 3DCRT, IMRT, and proton therapy when irradiating the breast and regional nodes showed advantages of using prot...
Source: Radiotherapy and Oncology - Category: Radiology Authors: Tags: Original Article Source Type: research
Abstract Purpose: To study the potential consequences of differences in the evaluation of variable versus uniform relative biological effectiveness calculations in proton radiotherapy for prostate cancer.Methods and material: Experimental data with proton beams suggest that relative biological effectiveness increases with linear energy transfer. This relation also depends on the [Formula: see text] ratio, characteristic of a tissue and a considered endpoint. Three phenomenological models (Carabe et al., Wedenberg et al. and McNamara et al.) are compared to a mechanistic model based on microdosimetry...
Source: Acta Oncologica - Category: Cancer & Oncology Authors: Tags: Acta Oncol Source Type: research
PMID: 32421456 [PubMed - as supplied by publisher]
Source: Acta Oncologica - Category: Cancer & Oncology Authors: Tags: Acta Oncol Source Type: research
Conclusions: The SPArc_seq optimization algorithm could effectively reduce the BDT compared to the original SPArc algorithm. The improved efficiency of the SPArc_seq algorithm has the potential to increase patient throughput, thereby reducing the operation cost of proton therapy. PMID: 32421375 [PubMed - as supplied by publisher]
Source: Acta Oncologica - Category: Cancer & Oncology Authors: Tags: Acta Oncol Source Type: research
ConclusionsRe-irradiation with proton therapy is a safe and effective treatment in patients with recurrent glioblastoma. Proton therapy does not negatively effect on HRQOL, but rather it seems to preserve HRQOL until the time of disease progression.
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research
Conclusion: Image-guided hypofractionated PT for centrally-located early-stage NSCLC provides excellent local control with low rates of grade ≥3 toxicities. For tumors in sensitive locations, PT may provide safer treatment than photon-based treatments due to its dosimetric advantages. PMID: 32394776 [PubMed - as supplied by publisher]
Source: Acta Oncologica - Category: Cancer & Oncology Authors: Tags: Acta Oncol Source Type: research
With proton therapy, high target coverage can be achieved, while sparing dose to organs-at-risk (OARs) [1,2]. This makes it especially attractive for tumours with many surrounding OARs, such as cancers in the brain [3], skull base [4 –6], head and neck [7,8] or lung [9]. Recently, the potential of proton therapy has been assessed for non-small cell lung cancer (NSCLC) treatments [10–13], with the main concern being intra-fractional variability. To mitigate these effects, rescanning [14], gating [10], tracking [15] or 4D-opti misation [16,17] have all been investigated.
Source: Radiotherapy and Oncology - Category: Radiology Authors: Tags: Original Article Source Type: research
More News: Cancer | Cancer & Oncology | Marketing | Pharmaceuticals | Proton Therapy